{'52WeekChange': -0.54678637,
 'SandP52WeekChange': None,
 'address1': 'Marina One East Tower',
 'address2': 'No. 12-00, 7 Straits View',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.1,
 'askSize': 1300,
 'averageDailyVolume10Day': 319912,
 'averageVolume': 387180,
 'averageVolume10days': 319912,
 'beta': -0.004048,
 'beta3Year': None,
 'bid': 9.26,
 'bidSize': 800,
 'bookValue': 0.603,
 'category': None,
 'circulatingSupply': None,
 'city': 'Singapore',
 'companyOfficers': [],
 'country': 'Singapore',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.69,
 'dayLow': 9.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.215,
 'enterpriseToRevenue': 14.126,
 'enterpriseValue': 241812016,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 10.149428,
 'fiftyTwoWeekHigh': 39.98,
 'fiftyTwoWeekLow': 6.61,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 4732128,
 'forwardEps': -2.48,
 'forwardPE': -3.733871,
 'fromCurrency': None,
 'fullTimeEmployees': 301,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.18128,
 'heldPercentInstitutions': 0.88762003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/wavelifesciences.com',
 'longBusinessSummary': 'Wave Life Sciences Ltd., a clinical stage genetic '
                        'medicine company, designs, optimizes, and produces of '
                        'novel stereopure oligonucleotides through PRISM, a '
                        'discovery and drug developing platform. The company '
                        'is primarily developing oligonucleotides that target '
                        'genetic defects to either reduce the expression of '
                        'disease-promoting proteins or transform the '
                        'production of dysfunctional mutant proteins into the '
                        'production of functional proteins. It focuses on '
                        'programs in neurology in the central nervous system '
                        'and neuromuscular system. The company has a research, '
                        'license, and option agreement with Pfizer Inc. and '
                        'Takeda Pharmaceutical Company Limited for the '
                        'research, development, and commercialization of '
                        'stereopure oligonucleotide therapeutics and '
                        'oligonucleotide therapeutics; and research, '
                        'development, and develop antisense oligonucleotides. '
                        'Wave Life Sciences Ltd. was founded in 2012 and is '
                        'based in Singapore.',
 'longName': 'Wave Life Sciences Ltd.',
 'market': 'us_market',
 'marketCap': 330880192,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_256557334',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -196931008,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.65,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '65 6236 3388',
 'previousClose': 9.59,
 'priceHint': 2,
 'priceToBook': 15.356551,
 'priceToSalesTrailing12Months': 19.329372,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.69,
 'regularMarketDayLow': 9.22,
 'regularMarketOpen': 9.65,
 'regularMarketPreviousClose': 9.59,
 'regularMarketPrice': 9.65,
 'regularMarketVolume': 229067,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35732200,
 'sharesPercentSharesOut': 0.1455,
 'sharesShort': 5197539,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4693472,
 'shortName': 'Wave Life Sciences Ltd.',
 'shortPercentOfFloat': 0.2026,
 'shortRatio': 13.34,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'WVE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -5.736,
 'twoHundredDayAverage': 9.104964,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b166faa2-4f38-3226-ab53-f1e915ebcf51',
 'volume': 229067,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.wavelifesciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '018936'}